Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats

Gabor Imre*, Dirk S. Fokkema, Gert J. Ter Horst

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    19 Citations (Scopus)

    Abstract

    Acute treatment with LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate}, a potent and selective agonist for group 11 metabotropic glutamate receptors (mGlu2/3), has previously been shown to block some schizophrenia-like effects of N-methyl-D-aspartate (NMDA) receptor antagonists, suggesting a novel therapeutic strategy for schizophrenia. The present study examined the effects of subchronic pretreatment with LY354740 (0.3, 3 and 10 mg/kg i.p.) on ketamine-evoked (12 mg/kg s.c.) prepulse inhibition deficits, hyperlocomotion and c-fos expression. At all doses, LY354740 failed to reverse both behavioral and neuronal effects of the ketamine. These results therefore do not support the putative antipsychotic role of LY354740. (c) 2006 Elsevier B.V All rights reserved.

    Original languageEnglish
    Pages (from-to)77-81
    Number of pages5
    JournalEuropean Journal of Pharmacology
    Volume544
    Issue number1-3
    DOIs
    Publication statusPublished - 21-Aug-2006

    Keywords

    • mGlu2/3 receptor
    • prepulse inhibition
    • locomotion
    • c-fos expression
    • schizophrenia
    • METABOTROPIC GLUTAMATE RECEPTORS
    • GROUP-II
    • PREFRONTAL CORTEX
    • PREPULSE INHIBITION
    • LOCOMOTOR-ACTIVITY
    • DOPAMINE RELEASE
    • AGONIST
    • PHENCYCLIDINE
    • SCHIZOPHRENIA
    • MODELS

    Cite this